Zuellig Pharma launches Eli Lilly's Mounjaro for obesity and diabetes treatment in Thailand, available from late May 2025.
The launch of Mounjaro, a novel treatment for obesity and diabetes, in Thailand represents a significant advancement in chronic disease management. It provides Thai patients with access to a cutting-edge therapy, potentially improving health outcomes and capturing a substantial share of the growing diabetes and obesity treatment market for Zuellig Pharma.
This product launch specifically targets the Thai market, addressing the growing prevalence of obesity and diabetes in Southeast Asia and demonstrating Zuellig Pharma's role in introducing advanced treatments to the region.
Indicated for obesity and diabetes treatment.
Available from late May 2025.
Mounjaro (tirzepatide) launched in Thailand.
Indicated for obesity and diabetes treatment.
Available from late May 2025.
Zuellig Pharma has launched Eli Lilly's innovative medicine, Mounjaro® (tirzepatide), in Thailand. This medicine is indicated for the treatment of obesity and diabetes. Its availability from late May 2025 aims to provide a new therapeutic option for patients managing these chronic conditions in the Thai market.
Sign in to save notes on signals.
Sign In